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Abstract
Background: Sarcopenia (the age-related loss of muscle mass and function) is a major contributor to loss of mobility,
falls, loss of independence, morbidity and mortality in older people. Although resistance training is effective in preventing
and reversing sarcopenia, many older people are sedentary and either cannot or do not want to exercise. This trial
examines the efficacy of supplementation with the amino acid leucine and/or angiotensin converting enzyme inhibition
to potentially improve muscle mass and function in people with sarcopenia. Promising preliminary data exist from small
studies for both interventions, but neither has yet been tested in adequately powered randomised trials in patients with
sarcopenia.
Methods: Leucine and ACE inhibitors in sarcopenia (LACE) is a multicentre, masked, placebo-controlled, 2 × 2 factorial
randomised trial evaluating the efficacy of leucine and perindopril (angiotensin converting enzyme inhibitor (ACEi)) in
patients with sarcopenia. The trial will recruit 440 patients from primary and secondary care services across the UK. Male
and female patients aged 70 years and over with sarcopenia as defined by the European Working Group on Sarcopenia
(based on low total skeletal muscle mass on bioimpedance analysis and either low gait speed or low handgrip strength)
will be eligible for participation. Participants will be excluded if they have a contraindication to, or are already taking, an
ACEi, angiotensin receptor blocker or leucine. The primary clinical outcome for the trial is the between-group difference
in the Short Physical Performance Battery score at all points between baseline and 12 months. Secondary outcomes
include appendicular muscle mass measured using dual-energy X-ray absorptiometry, muscle strength, activities of daily
living, quality of life, activity using pedometer step counts and falls. Participants, clinical teams, outcomes assessors and
trial analysts are masked to treatment allocation. A panel of biomarkers including microRNAs, neurohormones, genetic
polymorphisms and markers of inflammation relevant to muscle pathophysiology will be measured to explore predictors
of response and further elucidate mechanisms underlying sarcopenia. Participants will receive a total of 12 months of
either perindopril or placebo and either leucine or placebo.
Discussion: The results will provide the first robust test of the overall clinical and cost-effectiveness of these novel therapies
for older patients with sarcopenia.
Trial registration: ISRCTN, ISRCTN90094835. Registered on 18 February 2015.
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Background
Sarcopenia (the age-related loss of muscle mass and
function) is a major contributor to loss of mobility, falls,
loss of independence, morbidity and mortality in older
people [1]. The mechanisms behind the development of
sarcopenia are not fully understood, but accumulating
evidence suggests that the condition is multifactorial in
aetiology. Some of the factors involved are an altered
turnover of muscle protein with a reduction in muscle
protein synthesis and a relative increase in muscle pro-
tein breakdown, chronic inflammation with increased
cytokines including TNF and IL-6, inactivity, mitochon-
drial dysfunction and altered neuromuscular junction
structure and function [2]. Currently, the intervention
with the most evidence for efficacy in preventing and re-
versing sarcopenia is resistance exercise training [3].
However, many older people are sedentary, and either
cannot exercise or do not want to exercise.
Non-exercise interventions to prevent or counter the
effects of sarcopenia are thus required. A range of
potential interventions have been proposed, including
protein supplementation, myostatin inhibitors, testoster-
one and selective androgen receptor modifiers, growth
hormone and novel interventions including activin li-
gands [2]. Many of these approaches have either suffered
from frequent side effects (e.g. testosterone, growth hor-
mone) or are under evaluation in early-phase studies by
the pharmaceutical industry. The LACE trial studies the
efficacy of two promising interventions (leucine and
angiotensin converting enzyme inhibition) that can po-
tentially improve muscle mass and function in people
with sarcopenia as defined by the European Working
Group on Sarcopenia (EWGSOP) [4]. Promising prelim-
inary data exist from small trials for both interventions,
but neither has yet been tested in adequately powered
trials enrolling people with established sarcopenia.
Potential benefits of leucine therapy
Muscle protein synthesis in response to protein inges-
tion is attenuated in older people compared to younger
people (i.e. there is anabolic resistance to protein supple-
mentation) [5]. Increasing the amount of protein
ingested is one way of overcoming this issue, but older,
frail people typically already have sub-optimal protein
intakes and increasing their protein intake may be
challenging in practice.
Leucine, a branched-chain amino acid, is known to
have important regulatory actions, mediated at least in
part via the mammalian target of rapamycin (mTOR)
pathway. Leucine affects protein turnover, both by redu-
cing proteolysis and enhancing protein synthesis in vitro.
Studies in healthy older people confirm that addition of
leucine to a protein meal enhances muscle protein syn-
thesis [6–8]; previous studies suggest that approximately
2.5 g of leucine per meal is sufficient to generate the ef-
fect [9]. In addition, leucine stimulates insulin release by
pancreatic beta cells [10]; insulin signalling not only im-
proves glucose uptake by skeletal muscle, but is also an
important anabolic signal for skeletal muscle.
Potential benefits of ACE inhibitor therapy
The renin–angiotensin–aldosterone system activity has
been implicated in skeletal muscle dysfunction via mul-
tiple biological pathways [11]. Angiotensin II impairs
endothelial function and hence muscle blood supply, is
associated with increased levels of inflammation and
suppression of IGF-1, and has important effects on
mitochondrial function [12–14]. Aldosterone also has
deleterious effects, including lowering serum potassium,
impairment of endothelial function and promotion of fi-
brosis [15]. Conversely, ACEi drugs have been shown to
have multiple potentially beneficial effects on skeletal
muscle function. ACEi drugs improve endothelial func-
tion and angiogenesis and reduce inflammation. They
improve mitochondrial function, enhance IGF-1 levels,
promote skeletal muscle glucose uptake [16] and sup-
press pro-inflammatory cytokine levels such as IL-6 [17]
thought to have important effects on skeletal muscle.
Existing trial evidence
Leucine-enriched amino acid supplements have been
shown to improve muscle strength and function in
healthy older people, although one study of leucine
alone failed to replicate this effect [18, 19]. However, no
studies to date have examined the effect of leucine sup-
plementation alone specifically in people with diagnosed
sarcopenia. This is precisely the group, with lower IGF-1
signalling, lower protein intake and poor anabolic
response to protein loading, who are most likely to dem-
onstrate a response to intervention. Small trials of pro-
tein loading in frail older people show improvements in
physical performance measured using the Short Physical
Performance Battery test (1.0-point improvement at
24 weeks) [20] but no improvement in skeletal muscle
mass over this short follow-up period. In contrast, in
older participants undergoing resistance training, protein
supplementation enhanced muscle mass, but not muscle
strength or performance compared to placebo [21], sug-
gesting that it is the non-exercising majority of older,
frail people who are most likely to benefit from nutri-
tional efforts to enhance muscle protein synthesis.
There is some evidence that multiple biological func-
tions of ACEi drugs may translate into clinical benefit.
The ACEi perindopril produces a significant improve-
ment in physical function (31-m improvement in 6-
minute walk; improvement in quality of life of 0.09
points on the EQ5D tool) in functionally impaired older
people with a mean age 79 years [22]. Observational
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studies report better muscle strength and larger lower
extremity mass in older people taking an ACEi [23, 24].
However, studies of ACEi use in fitter older people have
not shown positive results [25], which suggests that the
effects of ACEi drugs may be more relevant in frailer
people. Similar to studies with leucine, combining an
ACEi with exercise training also had no effects beyond
those evident from exercise training; no additional
improvement in 6-minute walk was seen with perindo-
pril in our previous trial in which all participants were
undertaking an exercise programme [26]. Thus, the
existing evidence suggests that frail older people not en-
gaged in exercise training are the target population most
likely to benefit from ACEi therapy. ACEi drugs have
not yet been studied specifically in people with sarcope-
nia who have both poor muscle mass and function, and
providing evidence of efficacy in this group with a well-
defined specific deficit in muscle physiology is key to
testing whether ACEi drugs really have clinically relevant
benefit in the target population for this commissioned
call (i.e. people with sarcopenia).
Why the LACE trial is needed now
Sarcopenia underlies two of the most important medical
syndromes affecting older people—falls and immobility.
It is a major underlying cause of physical frailty in older
people, and is associated with a range of adverse out-
comes, including increased need for care, increased risk
of admission to care home, prolonged hospital stay and
increased mortality. As such, sarcopenia is a major cause
of morbidity in older people; hence, ways of preventing
or treating sarcopenia need to be tested.
To date, few large trials have been conducted of treat-
ments in trial populations selected explicitly to have sarco-
penia. Thus our knowledge of how best to conduct such
trials, as well as our knowledge of the best treatments to
use, is limited. It is against this background that the Effi-
cacy and Mechanisms Evaluation programme, funded by
the UK National Institute for Healthcare Research and the
UK Medical Research Council, released a commissioning
call in 2013 which led to the funding of this trial.
A key problem in pharmacotherapy for older people is
the issue of polypharmacy. The use of increasing numbers
of different medications (often to treat several co-existing
diseases) is a major cause of drug–drug interactions and
adverse events—which potentially outweigh any benefit of
adding new drugs. The choice of perindopril and leucine
as agents to test in this trial was informed in part by the
opportunity to use an agent present in the diet already
with a low risk of side-effects (leucine) and a medication
already commonly used in older people to treat conditions
including heart failure and hypertension (perindopril).
Using agents with multiple beneficial effects across a
range of disease states (pleiotropic agents) is one potential
way to maximise the benefit of pharmacotherapy in older,
multimorbid patients whist avoiding the pitfalls of
polypharmacy.
Trial objectives
The primary objective of the LACE trial is to determine
the efficacy of leucine and perindopril in improving phys-
ical function in older people with sarcopenia diagnosed
using the EWGSOP definition. Secondary objectives are
to evaluate the effect of leucine and perindopril on muscle
mass in older people and to evaluate biomarkers that can
predict response to leucine and perindopril in patients
with sarcopenia.
Methods
Study design
LACE is a multicentre, placebo-controlled, 2 × 2 factorial
randomised controlled trial analysed as randomised. Par-
ticipants will be randomised to receive either perindopril
or placebo, plus leucine or placebo. The intervention
and follow up will be for 1 year. Participants, clinical
teams, outcomes assessors and trial analysts are masked
to treatment allocation.
Study population
The study will recruit 440 community-dwelling partici-
pants aged 70 and over with sarcopenia according to the
EWGSOP definition [4]. Inclusion and exclusion criteria
are presented in Table 1, and the criteria for diagnosing
sarcopenia in the trial are presented in Table 2.
Potential participants are recruited from both primary
care and secondary care clinics, including Medicine for
the Elderly clinics, falls clinics and general medicine
clinics, at each site. Where local patient registries are
kept these are exploited to search for potentially suitable
participants. High numbers of patients need to be
screened, as patients cannot be identified by diagnosis
(sarcopenia is only rarely diagnosed in clinical practice
at present) and primary and secondary care electronic
systems in the UK do not hold data on physical function
that would facilitate identification of those who are more
likely to have sarcopenia. A telephone pre-screening
phase is therefore included (Fig. 1). This allows rapid, ef-
ficient selection of participants most likely to pass a
screening visit, and represents the best available strategy
for practical screening in sarcopenia trials. Pre-screening
is based on a brief telephone conversation conducted by
the research nurse exploring any contraindications (e.g.
heart failure, taking ACEi) and on administration of the
SARC-F tool [27]. The SARC-F tool consists of five
questions about physical function, giving a score be-
tween 0 (best) and 10 (worst); the score has been devel-
oped to assist with screening for sarcopenia and
functional impairment. A threshold score is used to
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denote a high probability of having sarcopenia, and
prompts progression to a screening visit. The threshold
score was initially set at 4 points or above (out of 10)
but is reviewed regularly in the light of screening infor-
mation, and is adjusted up or down to maximise effi-
ciency of recruitment.
At the screening visit, muscle mass is determined
using bioimpedance analysis. This approach minimises
the need to perform large numbers of DEXA scans for
trial screening, thus reducing costs, enhancing partici-
pant convenience and improving recruitment efficiency.
The Akern BIA (Bioimpedance Analyser) 101 machine is
used at all sites, and appendicular muscle mass is calcu-
lated using the equation developed by Sergi et al. [28];
this equation was developed in a white, older European
population using the BIA 101 machine. Thresholds for
muscle mass are derived from the UK Biobank cohort
[29] and are stratified by body mass index for each sex;
such an approach ensures that participants with sarcope-
nic obesity are represented in the trial and is consistent
with the more recent Foundation for the National Insti-
tutes of Health (FNIH) consensus guideline on diagnos-
ing sarcopenia [30]
Primary care recruitment is carried out with the assist-
ance of the primary care research networks in Scotland
(SPCRN) and England (CRN). Network involvement via
the Ageing UKCRN specialty group assists with recruit-
ment, access to patients and access to network research
nurse time. Written informed consent is obtained from
all participants prior to enrolment; the full participation
information and consent form are accessible via Add-
itional files 1 and 2. Research ethics committee approval
has been given by the East of Scotland Research Ethics
Committee (reference 14/ES/1099). The trial is approved
by the UK Medicines and Healthcare Regulatory Agency
(EudraCT number 2014-003455-61) and the trial is reg-
istered online (www.isrctn.com, ISRCTN90094835). The
trial is funded by the UK National Institute of Health-
care Research (NIHR) and Medical Research Council
Table 1 Inclusion and exclusion criteria for the LACE trial
Inclusion criteria
Age 70 and over
Diagnosis of sarcopenia (see Table 2)
Exclusion criteria
Contraindications or existing indications to therapies or placebo
Known clinical diagnosis of chronic heart failure (by European
Society of Cardiology criteria)
Confirmed LV systolic dysfunction on any imaging modality
Known aortic stenosis (peak gradient > 30 mmHg)
Systolic BP < 90 mmHg (supine)
Dizziness on standing associated with a postural drop of > 20/10 mmHg
(asymptomatic orthostatic hypotension is not a contraindication)
Serum creatinine > 170 μmol/L or eGFR < 30 ml/min by MDRD4
calculation
Serum potassium > 5.0 mmol/L
Serum sodium < 130 mmol/L
Using ACEi, angiotensin receptor blocker, aldosterone blocker or
leucine already (protein supplementation is permitted)
Previous adverse reaction to ACEi or leucine
Current use of oral NSAIDs (aspirin is permitted, as are topical NSAIDs)
Current use of potassium supplements, aliskiren, spironolactone or
other potassium-sparing diuretics
Hereditary or idiopathic angioedema
Lactose intolerance
Contraindications to consent or undertaking study outcomes
Implantable cardioverter defibrillator or pacemaker with atrial sensing
lead (pacemakers with ventricular sensing lead only are allowed)
Peripheral oedema present above knee level
Unable to mobilise without human assistance (walking aids are
allowed)
Unable to give written informed consent
Currently enrolled in another intervention research study, or <
30 days since completing another intervention research study.
Concomitant enrolment in observational studies is permitted.
Overlap with other myopathic conditions or important confounders
Currently enrolled in a time-limited exercise-based rehabilitation
programme
Any progressive neurological or malignant condition with life
expectancy < 6 months
Severe chronic obstructive pulmonary disease (GOLD stage IV)
Known myositis or other established myopathy
Self-reported weight loss of > 10% in last 6 months (to exclude
significant cachexia)
Known uncontrolled thyrotoxicosis
Prednisolone use≥ 7.5 mg/day (or equivalent dose of other
glucocorticoids)
ACEi angiotensin converting enzyme inhibitor, BP blood pressure, eGFR
estimated glomerular filtration rate, GOLD Global initiative for chronic
Obstructive Lung Disease, LACE Leucine and Angiotensin Converting Enzyme
inhibitors in sarcopenia, LV left ventricular, MDRD4 Modification of Diet in
Renal Disease 4-component equation, NSAID non-steroidal
anti-inflammatory drug
Table 2 Screening thresholds for diagnosis of sarcopenia in the
LACE trial
Males Females
Walking speed over 4 m (m/s) < 0.8 < 0.8
Maximum handgrip strength (kg) < 30 < 20
Height-adjusted skeletal muscle mass:
BMI < 18.5 (kg/m2) ≤ 6.02 ≤ 5.25
BMI 18.5–24.9 (kg/m2) ≤ 7.14 ≤ 5.70
BMI 25.0–29.9 (kg/m2) ≤ 8.00 ≤ 6.19
BMI≥ 30 (kg/m2) ≤ 8.77 ≤ 6.72
Diagnosis requires low walking speed and/or low grip strength AND low
muscle mass
BMI body mass index, LACE Leucine and Angiotensin Converting Enzyme
inhibitors in sarcopenia
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(MRC) Efficacy and Mechanisms Evaluation programme
(reference 13/53/03). The Sponsor is Tayside Academic
Health Sciences Centre, a joint initiative of the Univer-
sity of Dundee and NHS Tayside, and the Sponsor pro-
ject number for this trial is 2013GR06. Trial
management is provided by Tayside Clinical Trials Unit
(UKCTU number 49). The protocol on which this report
is based is version 7.0, dated 27 April 2017.
Intervention
Participants are randomised to receive either perindopril
4 mg once daily or matching placebo, and to receive leu-
cine 2.5 g three times per day or matching placebo. The
perindopril/placebo is administered as oral capsules. Pla-
cebo and active capsules are identical in external appear-
ance. Perindopril tablets are over-encapsulated with a
hard gelatin capsule and backfilled with lactose. The pla-
cebo capsules are identical in appearance and packed
with lactose. The starting dose of perindopril is 2 mg
daily which is up-titrated to 4 mg after 2 weeks if toler-
ated and renal function, serum potassium levels and
blood pressure remain within defined limits (potassium
< 5.0 mmol/L, creatinine < 180 μmol/L and < 30 μmol/L
rise from baseline, systolic blood pressure > 90 mmHg).
Participants in the placebo group also undergo a ‘mock’
up-titration. If the 4 mg daily dose is not tolerated, par-
ticipants are down-titrated to the original 2 mg daily. If
2 mg is also not tolerated, medication is withdrawn.
The leucine/placebo is administered as a powder. A
1.5-ml scoop is provided and participants are instructed
to take three scoops (4.5 ml equivalent to 2.5 g of leu-
cine/placebo) three times per day. The placebo is match-
ing lactose powder. Participants are instructed that they
should mix the powder with food or drink. Exploratory
work with our local Older People’s Advisory Group indi-
cated that mixing the leucine powder with food or drink
was palatable, particularly if mixed with foods such as
yoghurt or orange juice.
Randomisation is conducted via a centrally controlled,
web-based Good Clinical Practice-compliant randomisa-
tion system, run by Tayside Clinical Trials Unit. Investi-
gators at each site access the web-based system to
randomise each participant at the end of the baseline
visit. Randomisation is stratified by site. To ensure
balanced assignment across critical variables, a mini-
misation algorithm is employed, using baseline age (> 80
Fig. 1 Participant flow through the trial. DXA dual-energy X-ray absorptiometry, EQ5D EuroQol 5D, FFQ Food Frequency Questionnaire, NEADL
Nottingham Extended Activities of Daily Living
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vs ≤ 80 years), sex, SPPB score (> 8 vs ≤ 8), grip strength
(> 25 vs ≤ 25 kg for males; > 15 vs ≤ 15 kg for females)
and Charlson co-morbidity score (> 3 vs ≤ 3) to balance
allocation across trial arms.
Participants are asked to return all unused study medi-
cation including empty bottles/containers. Adherence to
medication will be recorded by capsule count of the
perindopril/placebo capsules and by the weight of the
container for the leucine/placebo powder. Serum angio-
tensin converting enzyme (ACE) is measured to assess
adherence to the perindopril/placebo capsules. To
ensure that medication adherence is maximised, we em-
ploy a combination of written information about the
study medication and why taking it is important, to-
gether with aide memoirs including LACE-branded
mugs and fridge magnets. At each visit, participants are
reminded about the importance of medication adher-
ence. Interventions incorporating these components
have been shown in a Cochrane review to enhance
adherence [31]. If one of the study drugs needs to be
stopped or the participant wishes to stop, they are
encouraged to continue with the other study drug. Par-
ticipants stopping both study drugs are encouraged to
remain in the study in order to facilitate analysis as
randomised.
Outcomes
The primary outcome for the trial is the Short Physical
Performance Battery, measured at baseline, 3, 6, 9 and
12 months. The between-group difference in the SPPB
across the whole follow up will be reported as the primary
outcome, calculated using generalised estimating equa-
tions to incorporate repeated measures and missing data.
The SPPB is a validated measure of lower limb function
that reflects everyday activity. It is a powerful predictor of
subsequent disability, institutionalisation and death in
older people [32–34], and has more data validating its use
in older people than any other measure of physical
function. Secondary outcomes include between-group dif-
ferences in muscle mass measured by dual X-ray absorpti-
ometry, other measures of physical function, instrumental
activities of daily living and quality of life. We also meas-
ure blood pressure, insulin resistance, hip bone mineral
density and a panel of biomarkers to explore both mecha-
nisms of disease and predictors of response to treatment.
Key outcomes and times of collection are listed as part of
the SPIRIT figure (Fig. 2).
In addition, we are collecting data on adverse events,
falls, hospitalisation, death and admission to institutional
care. Consent is obtained for open-label follow up of
participants for these outcomes collected from routine
clinical data following the end of the 1-year study period.
We are collecting data on usual physical activity and diet
at baseline and 12 months using step counts measured
by an OMRON pedometer and the Scottish Collabora-
tive Group Food Frequency Questionnaire (FFQ)
respectively; this will allow the interaction between treat-
ment and protein intake (total, plant vs animal protein)
to be ascertained.
Statistical analysis
Analyses will be by group as randomised and will com-
ply with the International Conference on Harmonisation
(ICH) E9 ‘Statistical Principles for Clinical Trials’ [35].
Two-sided p < 0.05 will be taken as significant for all
analyses. The primary analysis will be a repeated-
measures, mixed-model between-group comparison of
SPPB utilising all available data points during follow up.
Initially, a test for treatment interaction between peri-
ndopril and leucine will be carried out and if not signifi-
cant the main analysis will proceed using the full power
of the factorial design; each intervention will be assessed
separately as an independent hypothesis. Treatment ef-
fect estimates for all primary and secondary outcomes
will be adjusted for baseline values, age, sex and mini-
misation variables.
Secondary outcomes will be analysed with similar
methodology using repeated-measures, mixed-model,
between-group comparisons. Unadjusted and adjusted
analyses will be presented as already discussed. Sensitiv-
ity analyses will be performed to further test the effect of
missing data both by multiple imputation and by assign-
ing worst-possible result status to missing data points. A
supplementary per-protocol analysis will be performed
to examine adverse events in those taking at least 80% of
their study medication.
No interim analyses are planned. Exploratory sub-
group analyses will be performed, including examining
differences in treatment effects by age (above and below
median), SPPB (> 8 vs ≤ 8) and sex. A full Statistical
Analysis Plan will be prepared and finalised prior to trial
database lock, and will be made available as an add-
itional upload on the Trials website once finalised.
Biomarkers sub-study
The analytes that will be investigated in the biomarker
sub-study can be divided into three main groups; those
that reflect the activity of the renin–angiotensin system
or its targets, those that are markers of protein turnover
and those potential novel markers of regenerative cap-
acity that may reflect the capacity to respond to treat-
ment. To look at the activity of the renin–angiotensin
system we will measure circulating levels of ACE and
renin as well as two truncated forms of angiotensin
(ang(1–7) and ang(1–9)) that have been shown to alter
muscle mass and are likely to be modified by an ACEi
[36, 37]. There are a number of different processes
through which activation of the renin–angiotensin
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Fig. 2 SPIRIT diagram for the LACE trial. 6MWD six minute walking distance, ACE angiotensin converting enzyme, BIA bioimpedance analysis, DXA
dual-energy X-ray absorptiometry, eGFR estimated glomerular filtration rate, EQ5D EuroQol 5D, FFQ Food Frequency Questionnaire, IMP investigational
medicinal product, NEADL Nottingham Extended Activities of Daily Living, SPPB Short Physical Performance Battery
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system is thought to contribute to muscle loss, including
increased inflammatory cytokine production, reduced
IGF-1 production and increased myostatin production in
signalling [38]. We will therefore quantify IL-6, TNF-α
and myostatin. We will also quantify circulating levels of
GDF-15, another member of the TGF-β family of cyto-
kines, as it is a marker of all-cause mortality and is asso-
ciated with muscle mass in patients with COPD [39] and
with muscle loss following surgery [40]. The influence of
specific polymorphic variation in the renin–angiotensin
system will also be analysed.
To identify changes in muscle protein turnover in the
absence of direct measurements, which are expensive
and invasive, we will quantify pro-collagen III N-
terminal peptide as a measure of new collagen synthesis
[41] and levels of circulating muscle restricted miRNAs
(myomiRs) that are increased in the circulation of
patients with diseases associated with muscle wasting in-
cluding Duchenne muscular dystrophy [42] and in
chronic obstructive pulmonary disease [43].
Finally, we will examine circulating levels of a set of
imprinted miRNAs that may reflect the regenerative
capacity of the individual. These miRNAs include miR-
518e from a paternally expressed cluster on chromo-
some 19 and miR-485-3p from a maternally expressed
cluster on chromosome 14 which we have shown to be
associated with muscle phenotype in patients with
COPD [44, 45].
Univariate analyses will be conducted examining the
interaction between individual baseline biomarker values
and treatment effect for muscle mass and the SPPB at
12 months, and between biomarker change between
baseline and 3 months and treatment effect for muscle
mass and the SPPB at 12 months. In addition, multivari-
able analysis for baseline values including age, sex, SPPB,
grip, muscle mass, albumin, creatinine, all measured bio-
markers and treatment group will be conducted to
examine whether baseline values or change at 3 months
predicts the SPPB change and muscle mass change at
12 months.
Sample size calculation
We have taken a deliberately conservative approach and
used the minimum clinically important difference
(MCID) for the SPPB to ensure we have proof of effi-
cacy. In order to detect a MCID in the SPPB of 0.5
points (anticipated SPPB of 8 in the placebo group and
8.5 in the intervention group, SD = 2.7 points [46]) with
a power of 90% at α = 0.05, and assuming a correlation
between time points of 0.7 as seen from previous work
[26], we would require a total of 352 participants (88 for
each of the four groups). Assuming 20% dropout at
12 months (a rate of attrition consistent with that seen
in previous trials of ACEi in frail older people [26]), we
therefore need to recruit 440 patients. This sample size
will also have 90% power to detect a 5% difference in
muscle mass at 12 months, assuming a baseline value of
19 kg (SD = 2.8) for total skeletal muscle mass [47].
Trial oversight and monitoring
Trial oversight is provided by an independent Trial
Steering Committee (TSC), which meets at least every
6 months. Members include academic geriatricians with
trials experience and three lay members, together with
the chief investigator. The TSC reviews trial progress,
approves any significant protocol changes, advises on
trial conduct and approves analysis plans and dissemin-
ation plans. The TSC reports to the funder (NIHR), who
has final decision-making authority for the trial. An in-
dependent Data Monitoring Committee (DMC) meets at
least every 6 months; this committee comprises three in-
dependent members, chaired by an academic geriatrician
with trials experience, and contains a minimum of one
independent statistician. The DMC reviews trial adverse
events and safety data, and makes recommendations to
the TSC. Charters for conduct of the TSC and the DMC
are available from the study team and from the funder.
Routine management of the trial is provided by the Trial
Management Group (TMG), which comprises the grant
co-applicants, local site investigators, trials unit
personnel from project management, data management
and statistics teams, Sponsor representatives and Spon-
sor monitors.
Monitoring of the trial conduct at each site is provided
by the Sponsor. Monitoring takes place according to a
pre-specified plan, with site visits conducted according
to the recruitment rate and frequency of problems iden-
tified by remote monitoring of study data. Both the
Sponsor and the Clinical Trials Unit are subject to peri-
odic audit by the UK Medicines and Healthcare products
Regulatory Agency. The funder provides monitoring of
overall trial progress, with additional input from the in-
dependent TSC. The final decision to publish lies with
the funder (NIHR) and the Sponsor; the funder and the
Sponsor have both reviewed the study design. The Spon-
sor will have no input into data collection, analysis and
interpretation; the final report will be peer reviewed by
the Funder prior to finalisation.
Protocol amendments
Significant protocol amendments are implemented
across all sites after approval by the Sponsor, the inde-
pendent TSC, the funder, the ethics review board, the
UK Medicines and Healthcare products Regulatory
Agency and the UK Health Research Authority. The
current protocol is available via the NIHR website and
via the trial website (www.lacetrial.org.uk).
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Data confidentiality and post-trial care
Trial data are held separately from personal identifiers,
on password-protected secure servers at the University
of Dundee. Identifiable data will not be shared outside
the trial team or Sponsor without written participant
consent. De-identified trial data will be stored for
15 years after the end of the trial. Supplies of trial medi-
cation will not be made available to participants after the
end of the trial, but both interventions are available via
either prescription or via health shops. Compensation
for harm suffered as a result of trial interventions or
processes will be available via UK National Health Ser-
vice compensation or via University of Dundee trial
indemnity.
Authorship and dissemination
Authorship for the main trial results will be based on
the International Committee of Medical Journal Editors
authorship criteria, and will include, but not be limited
to, grant co-applicants, local investigators, trial man-
agers, statisticians and data analysts fulfilling these
criteria. Dissemination of results will take place via mul-
tiple routes: presentation at scientific conferences; publi-
cation in scientific journals and via the NIHR library;
presentations to participants and their families; written
summaries of results to participants; and presentations
to local healthcare teams. Results will be uploaded to the
EudraCT and ISRCTN databases.
Discussion
Initial screening criteria for muscle mass in the trial used
the Janssen equation to calculate muscle mass [48], and
used conservative thresholds for total skeletal muscle
mass: 13 kg for women and 20.5 kg for men. Initial ex-
perience with screening found that these criteria were
too stringent—only 5% of those screened had eligible
skeletal muscle mass. Further investigation suggested
that the Janssen equation had systematic inaccuracies at
low skeletal muscle mass, and our thresholds did not ac-
count for body mass index—thus excluding patients with
sarcopenic obesity. Since changing to the screening
thresholds described in this article, the screening pass
rate now approaches 50% and recruitment has conse-
quently accelerated.
Because sarcopenia is not a diagnosis commonly made
in clinical practice (it received an ICD-10 code only in
September 2016), case-finding for sarcopenia trials is
challenging and few centres in the UK have experience
recruiting to trials for sarcopenia. A supplementary aim
of the LACE trial programme is therefore to determine
efficient ways of finding and screening potential partici-
pants for sarcopenia trials. We will evaluate the success
of recruitment from primary versus secondary care; the
best threshold on the SARC-F to identify eligible
participants on telephone pre-screening; the best com-
bination of search terms to use in primary care elec-
tronic system searches; and the best ways of engaging
participants from a range of secondary care clinics. Ini-
tial experience suggests that primary care recruitment is
much more successful than recruitment from geriatric
medicine secondary care services. Although one might
expect patients with sarcopenia to be concentrated in
such secondary care clinics, this patient group has mul-
tiple exclusion criteria, particularly use of ACEi drugs
and the presence of dementia. The overall number of pa-
tients in geriatric medicine clinics is small compared to
the volume of potential participants in primary care; the
lower percentage of eligible patients in primary care
makes efficient searches, mailshots and telephone pre-
screening essential. We are setting up a centralised tele-
phone facility to manage the large volume of telephone
pre-screening required by this approach.
A final aim is to build capacity across a network of UK
sites to recruit to and deliver sarcopenia trials. We an-
ticipate that the experience gained by UK sites in the
trial, along with other initiatives such as the British Geri-
atrics Society Sarcopenia and Frailty Research Group
[49], will aid in the establishment of this UK Sarcopenia
Trials Network. This network, and the expertise devel-
oped by centres through LACE, should accelerate clin-
ical trial activity in this emerging and important area of
medicine.
Trial status
The trial started recruitment in July 2016, and results
are expected towards the end of 2020.
Additional files
Additional file 1: Informed consent form for the LACE trial. (PDF 29 kb)
Additional file 2: Participant information leaflet for the LACE trial.
(PDF 467 kb)
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